Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease
- PMID: 19204022
- PMCID: PMC2823571
- DOI: 10.1136/jnnp.2008.158964
Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease
Erratum in
- J Neurol Neurosurg Psychiatry. 2009 Sep 1;80(9):1056
Abstract
Background: Patients using cholinesterase inhibitors (ChEIs) have a delay in nursing home (NH) admission compared with those who were not using the medication. There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD). This study was conducted to examine the effects of ChEIs and memantine on time to death and time to NH admission.
Methods: Time to NH admission and death was examined in 943 probable AD patients who had at least a 1-year follow-up evaluation. Of these patients, 140 (14.9%) used both ChEIs and memantine, 387 (41%) [corrected] used only ChEIs, and 416 (44.1%) [corrected] used neither. The mean (SD) follow-up time was 62.3 (35.8) months. The analysis was conducted with multivariable Cox proportional hazard models controlling for critical covariates (ie, age, education level, gender, severity of the dementia, hypertension, diabetes mellitus, heart disease, psychiatric symptoms and use of psychotropic medications).
Results: Compared with those who never used cognitive enhancers, patients who used ChEIs had a significant delay in NH admission (HR: 0.37, 95% CI 0.27 to 0.49); this effect was significantly augmented with the addition of memantine (HR: 0.29, 95% CI 0.11 to 0.72) (memantine+ChEI vs ChEI alone). ChEIs alone, or in combination with memantine had no significant association on time to death.
Conclusions: This observational study revealed that the addition of the NMDA receptor antagonist memantine to the treatment of AD with ChEI significantly altered the treated history of AD by extending time to nursing home admission.
Figures
Similar articles
-
Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.JAMA Netw Open. 2018 Nov 2;1(7):e184080. doi: 10.1001/jamanetworkopen.2018.4080. JAMA Netw Open. 2018. PMID: 30646339 Free PMC article.
-
The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.Eur J Health Econ. 2014 Nov;15(8):791-800. doi: 10.1007/s10198-013-0523-y. Epub 2013 Aug 9. Eur J Health Econ. 2014. PMID: 23928827 Free PMC article.
-
[Cholesterol inhibitor and memantine in symptomatic dementia therapy].Praxis (Bern 1994). 2013 Feb 27;102(5):293-300; discussion 298-9. doi: 10.1024/1661-8157/a001209. Praxis (Bern 1994). 2013. PMID: 23446240 Review. German. No abstract available.
-
Longitudinal medication usage in Alzheimer disease patients.Alzheimer Dis Assoc Disord. 2010 Oct-Dec;24(4):354-9. doi: 10.1097/WAD.0b013e3181e6a17a. Alzheimer Dis Assoc Disord. 2010. PMID: 20625271 Free PMC article.
-
Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.J Clin Psychiatry. 2006;67 Suppl 3:15-22; quiz 23. J Clin Psychiatry. 2006. PMID: 16649847 Review.
Cited by
-
Therapeutic Targets in Innate Immunity to Tackle Alzheimer's Disease.Cells. 2024 Aug 26;13(17):1426. doi: 10.3390/cells13171426. Cells. 2024. PMID: 39272998 Free PMC article. Review.
-
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias.Pharmacoeconomics. 2024 Dec;42(12):1373-1394. doi: 10.1007/s40273-024-01418-3. Epub 2024 Sep 9. Pharmacoeconomics. 2024. PMID: 39249730 Free PMC article.
-
Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now?Pharmaceutics. 2024 May 24;16(6):708. doi: 10.3390/pharmaceutics16060708. Pharmaceutics. 2024. PMID: 38931832 Free PMC article. Review.
-
Alzheimer's disease and its treatment-yesterday, today, and tomorrow.Front Pharmacol. 2024 May 24;15:1399121. doi: 10.3389/fphar.2024.1399121. eCollection 2024. Front Pharmacol. 2024. PMID: 38868666 Free PMC article. Review.
-
Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study.Alzheimers Res Ther. 2024 May 29;16(1):117. doi: 10.1186/s13195-024-01481-0. Alzheimers Res Ther. 2024. PMID: 38812028 Free PMC article.
References
-
- Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer’s disease in the US population. Prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119–1122. - PubMed
-
- Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998;51:728–733. - PubMed
-
- Lopez OL, Wisniewski SR, Becker JT, et al. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer’s disease. Arch Neurol. 1999;56:1266–1272. - PubMed
-
- Eaker ED, Vierkant RA, Mickel SF. Predictors of nursing home admission and/or death in incident Alzheimer’s disease and other dementia cases compared to controls: a population-based study. J Clin Epidemiol. 2002;55:462–468. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AG027224-04/AG/NIA NIH HHS/United States
- R56 AG020098/AG/NIA NIH HHS/United States
- U01 AG016976/AG/NIA NIH HHS/United States
- P50 AG005133-25/AG/NIA NIH HHS/United States
- AG05133/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- R01 AG020098/AG/NIA NIH HHS/United States
- R01 AG027224/AG/NIA NIH HHS/United States
- AG03705/AG/NIA NIH HHS/United States
- AG027224/AG/NIA NIH HHS/United States
- AG16976/AG/NIA NIH HHS/United States
- P50 AG005133-26/AG/NIA NIH HHS/United States
- P50 AG005133-210020/AG/NIA NIH HHS/United States
- AG20098/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical